Safety and Feasibility of Metformin for Sepsis Induced AKI
Launched by HERNANDO GOMEZ · Jun 2, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Acute kidney injury (AKI) is an independent risk factor for death, that affects 10-15% of hospitalized patients and more than 50% of patients admitted to the intensive care unit. The most frequent cause of AKI is Sepsis which affects 48 million people worldwide every year. Importantly, the 6-8-fold increase in the risk of death that AKI carries in sepsis, may be reversible because patients with sepsis who recover from AKI have similar 1- and 3-year mortality as those without AKI. These data agree with evidence showing that the development of AKI carries far-reaching consequences like remote...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \> 18 years
- • 2. Admitted to the ICU with sepsis per sepsis 3 criteria (defined as suspected infection or initiation of anti-biotics plus an increase in SOFA ≥ 2 points)
- • 3. Available enteral access
- Exclusion Criteria:
- • 1. Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2 prior to study drug administration
- • 2. Not expected to survive more than 24 hours
- • 3. Advanced directive to withhold life-sustaining treatment
- • 4. Metformin use in the last 30 days from admission (assessed by medical or refill prescription history, and by medication reconciliation)
- • 5. The treating clinician believes that participation in the trial would not be in the best interests of the patient
- • 6. Known or suspected pregnancy
- • 7. On mechanical circulatory support of any kind
- • 8. History of allergy to metformin
- • 9. Having severe metabolic acidosis defined by a venous or arterial pH \< 7.2, with PaCO2 \< 45 or PvCO2 \< 50 mmHg at the time of enrolment.
- • Patients co-enrolled in observational studies will be eligible for enrollment in LiMiT AKI. However, patients enrolled in interventional studies will need to be assessed on an individual basis to define whether the patient will be eligible.
- • Children will be excluded from recruitment for this study. Etiologic causes of sepsis, acute kidney injury, and prognostic factors for children differ from those for adults; and for these reasons the proposed study focuses only on the adult population (age 18 years or older).
About Hernando Gomez
Hernando Gomez is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative and ethical clinical studies. With a strong focus on developing novel therapies and treatment modalities, our organization collaborates with leading researchers and healthcare institutions to ensure rigorous trial design and execution. We prioritize patient safety and data integrity, striving to contribute meaningful insights to the scientific community and enhance the quality of care across various therapeutic areas. Through our efforts, we aim to bridge the gap between scientific discovery and clinical application, fostering a healthier future for all.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Hernando Gomez, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported